The Clorox Company (CLX)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $13.26B
Last updated: Nov 17, 2026 at 11:05 AM ET
The Clorox Company (CLX) Earnings: Report Dates and Results
The Clorox Company (CLX) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, The Clorox Company reported EPS of $1.55, above the $0.97 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CLX has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 29.5% below the $1.39 reported for the quarter ended Dec 31, 2025.
CLX Earnings Call
The latest CLX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CLX beat 32, missed 7 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.91B, up 33.6% from $1.43B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.55 | $0.97 | $0.87 - $1.20 | +59.79% | Beat | +82.4% | 15 | 1 up, 9 down | Nov 2, 2026 | $1.91B |
| Jun 30, 2026 | $1.66 | $1.64 | $1.59 - $1.71 | +1.22% | Beat | -42.2% | 14 | 0 up, 2 down | Aug 3, 2026 | $1.95B |
| Mar 31, 2026 | $1.64 | $1.54 | $1.33 - $1.67 | +6.49% | Beat | +13.1% | 16 | 1 up, 9 down | Apr 30, 2026 | $1.67B |
| Dec 31, 2025 | $1.39 | $1.43 | $1.33 - $1.51 | -2.80% | Miss | -10.3% | 14 | 0 up, 3 down | Feb 3, 2026 | $1.67B |
| Sep 30, 2025 | $0.85 | $0.78 | $0.60 - $0.96 | +8.97% | Beat | -54.3% | 14 | 1 up, 8 down | Nov 3, 2025 | $1.43B |
| Jun 30, 2025 | $2.87 | $2.21 | $2.07 - $2.46 | +29.86% | Beat | +57.7% | 15 | 3 up, 7 down | Jul 31, 2025 | $1.99B |
| Mar 31, 2025 | $1.45 | $1.56 | $1.48 - $1.64 | -7.05% | Miss | -15.2% | 15 | 2 up, 9 down | May 5, 2025 | $1.67B |
| Dec 31, 2024 | $1.55 | $1.40 | $1.24 - $1.57 | +10.71% | Beat | -28.2% | 14 | 5 up, 2 down | Feb 3, 2025 | $1.69B |
| Sep 30, 2024 | $1.86 | $1.39 | $1.28 - $1.57 | +33.81% | Beat | +279.6% | 14 | 6 up, 1 down | Oct 30, 2024 | $1.76B |
| Jun 30, 2024 | $1.82 | $1.56 | $1.42 - $1.64 | +16.67% | Beat | +9.0% | 15 | 3 up, 0 down | Aug 1, 2024 | $1.90B |
| Mar 31, 2024 | $1.71 | $1.37 | $1.23 - $1.63 | +24.82% | Beat | +13.2% | 14 | 0 up, 0 down | Apr 30, 2024 | $1.81B |
| Dec 31, 2023 | $2.16 | $1.10 | $0.80 - $1.29 | +96.36% | Beat | +120.4% | 15 | 3 up, 1 down | Feb 1, 2024 | $1.99B |
| Sep 30, 2023 | $0.49 | -$0.23 | -$0.40 - -$0.03 | +313.04% | Beat | -47.3% | 13 | 0 up, 0 down | Nov 1, 2023 | $1.39B |
| Jun 30, 2023 | $1.67 | $1.18 | $1.03 - $1.38 | +41.53% | Beat | +79.6% | 14 | 4 up, 0 down | Aug 2, 2023 | $2.02B |
| Mar 31, 2023 | $1.51 | $1.22 | $1.02 - $1.41 | +23.77% | Beat | +15.3% | 16 | 6 up, 0 down | May 2, 2023 | $1.92B |
| Dec 31, 2022 | $0.98 | $0.66 | $0.46 - $0.81 | +48.48% | Beat | +48.5% | 16 | 3 up, 1 down | Feb 2, 2023 | $1.72B |
| Sep 30, 2022 | $0.93 | $0.78 | $0.53 - $0.89 | +19.23% | Beat | -23.1% | 16 | 6 up, 1 down | Nov 1, 2022 | $1.74B |
| Jun 30, 2022 | $0.93 | $0.93 | $0.80 - $1.02 | 0.00% | In line | -2.1% | 13 | 2 up, 4 down | Aug 3, 2022 | $1.80B |
| Mar 31, 2022 | $1.31 | $0.96 | $0.78 - $1.12 | +36.46% | Beat | -19.1% | 13 | 1 up, 1 down | May 2, 2022 | $1.81B |
| Dec 31, 2021 | $0.66 | $0.85 | $0.69 - $1.03 | -22.35% | Miss | -67.5% | 15 | 4 up, 0 down | Feb 3, 2022 | $1.69B |
| Sep 30, 2021 | $1.21 | $1.02 | $0.80 - $1.15 | +18.63% | Beat | -62.4% | 15 | 0 up, 0 down | Nov 1, 2021 | $1.81B |
| Jun 30, 2021 | $0.95 | $1.31 | $1.19 - $1.97 | -27.48% | Miss | -60.6% | 15 | N/A | Aug 3, 2021 | $1.80B |
| Mar 31, 2021 | $1.62 | $1.46 | $1.29 - $1.80 | +10.96% | Beat | -14.3% | 14 | N/A | Apr 30, 2021 | $1.78B |
| Dec 31, 2020 | $2.03 | $1.75 | $1.59 - $2.01 | +16.00% | Beat | +39.0% | 15 | N/A | Feb 4, 2021 | $1.84B |
| Sep 30, 2020 | $3.22 | $2.25 | $2.06 - $2.59 | +43.11% | Beat | +102.5% | 13 | N/A | Nov 2, 2020 | $1.92B |
| Jun 30, 2020 | $2.41 | $1.99 | $1.87 - $2.08 | +21.11% | Beat | +28.2% | 13 | N/A | Aug 3, 2020 | $1.98B |
| Mar 31, 2020 | $1.89 | $1.63 | $1.38 - $1.98 | +15.95% | Beat | +31.3% | 13 | N/A | May 1, 2020 | $1.78B |
| Dec 31, 2019 | $1.46 | $1.33 | $1.25 - $1.35 | +9.77% | Beat | +4.3% | 14 | N/A | Feb 4, 2020 | $1.45B |
| Sep 30, 2019 | $1.59 | $1.54 | $1.48 - $1.62 | +3.25% | Beat | -1.9% | 15 | N/A | Oct 31, 2019 | $1.51B |
| Jun 30, 2019 | $1.88 | $1.84 | $1.80 - $1.86 | +2.17% | Beat | +13.3% | 15 | N/A | Aug 1, 2019 | $1.63B |
| Mar 31, 2019 | $1.44 | $1.47 | $1.39 - $1.51 | -2.04% | Miss | +5.1% | 17 | N/A | May 1, 2019 | $1.55B |
| Dec 31, 2018 | $1.40 | $1.31 | $1.23 - $1.41 | +6.87% | Beat | +20.7% | 16 | N/A | Feb 4, 2019 | $1.47B |
| Sep 30, 2018 | $1.62 | $1.59 | $1.48 - $1.66 | +1.89% | Beat | +11.0% | 16 | N/A | Oct 31, 2018 | $1.56B |
| Jun 30, 2018 | $1.66 | $1.59 | $1.52 - $1.62 | +4.40% | Beat | +8.5% | 16 | N/A | Aug 2, 2018 | $1.69B |
| Mar 31, 2018 | $1.37 | $1.31 | $1.28 - $1.34 | +4.58% | Beat | +4.6% | 14 | N/A | May 2, 2018 | $1.52B |
| Dec 31, 2017 | $1.16 | $1.23 | $1.18 - $1.26 | -5.69% | Miss | +1.8% | 16 | N/A | Feb 2, 2018 | $1.42B |
| Sep 30, 2017 | $1.46 | $1.42 | $1.38 - $1.45 | +2.82% | Beat | +7.4% | 14 | N/A | Nov 1, 2017 | $1.50B |
| Jun 30, 2017 | $1.53 | $1.49 | $1.46 - $1.54 | +2.68% | Beat | +21.4% | 17 | N/A | Aug 3, 2017 | $1.65B |
| Mar 31, 2017 | $1.31 | $1.30 | N/A | +0.77% | Beat | +8.3% | N/A | N/A | May 3, 2017 | $1.48B |
| Dec 31, 2016 | $1.14 | $1.22 | N/A | -6.56% | Miss | 0.0% | N/A | N/A | Feb 3, 2017 | $1.41B |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $5.54, down 28.3% from the year before. It was $5.34 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $5.54 | -28.3% |
| Jun 30, 2025 | $7.73 | +25.1% |
| Jun 30, 2024 | $6.18 | +21.4% |
| Jun 30, 2023 | $5.09 | +23.8% |
| Jun 30, 2022 | $4.11 | -47.4% |
| Jun 30, 2021 | $7.82 | +6.4% |
| Jun 30, 2020 | $7.35 | +15.9% |
| Jun 30, 2019 | $6.34 | +12.2% |
| Jun 30, 2018 | $5.65 | +5.8% |
| Jun 30, 2017 | $5.34 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,435 | 15 | |
| 2026Q2 | Jun 30, 2026 | 9,531 | 17 | |
| 2026Q1 | Mar 31, 2026 | 7,460 | 14 | |
| 2025Q4 | Dec 31, 2025 | 9,265 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,917 | 17 | |
| 2025Q2 | Jun 30, 2025 | 3,398 | 20 | |
| 2025Q1 | Mar 31, 2025 | 8,879 | 18 | |
| 2024Q4 | Dec 31, 2024 | 11,105 | 18 |
2026Q3 Earnings Call
Opening remarks
Lisah Burhan Vice President, Investor Relations Thank you. Good afternoon, and thank you for joining us. On the call with me today are Linda Rendle, our Chair and CEO; and Luc Bellet, our CFO. Please note that our earnings release and prepared remarks are available on our website at thecloroxcompany.com. Linda will share a few opening comments, and then we'll take your questions. During this call, we may make forward-looking statements, including about our fiscal 2026 outlook. These statements are based on management's current expectations but may differ from actual results or outcomes. In addition, we may refer to certain non-GAAP financial measures. Please refer to the forward-looking statements section, which identifies various factors that could affect such forward-looking statements, which has been filed with the SEC. In addition, please refer to the non-GAAP financial information section of our earnings release and the supplemental financial schedule in the Investor Relations section of our website for reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures. I'll now turn it over to Linda.
Linda Rendle Chair and CEO Thank you for joining us today. As we approached fiscal year 2026, we knew it would take a disciplined, phased approach. In the front half of the year, we intentionally focused on implementing and stabilizing our new ERP. That work was foundational to strengthening how we operate, even though we knew it would create some near-term disruption. As we moved into the back half, our focus turned to rebuilding momentum, getting innovation to shelf and sharpening execution. That sequencing is still the right one and it remains central to our plan. That said, the pace of improvement has been slower than we expected in some businesses and as a result, our third quarter results were mixed and fell short of our expectations. We continue to make progress on market share across much of the portfolio, but more gradually than we anticipated in certain categories. Gross margin also came in below expectations, driven by higher-than-expected supply chain costs and delayed cost savings as we deliberately prioritized stabilizing the ERP. Even with those challenges, we remain confident in the path forward. With the ERP implementation now complete, we're better positioned to convert our innovation, investments and distribution gains into value superiority for our brands and stronger results. Our focus is squarely on execution, delivering the fundamentals, accelerating innovation performance and finishing the year with momentum as we set up for fiscal year 2027. With that, Luc and I are happy to take your questions.
Operator Operator And our first question comes from Peter Grom with UBS Financial.
Peter Grom Analyst, UBS Financial I was hoping to start just on the top line trajectory. You touched on some of the macro pressures.
Frequently Asked Questions About CLX
When is The Clorox Company's next earnings date?
The Clorox Company's next earnings report is expected for Feb 1, 2027.
Did CLX beat earnings estimates last quarter?
Yes. The Clorox Company reported EPS of $1.55 for the quarter ended Sep 30, 2026, above the $0.97 estimate, a 59.79% surprise.
What EPS do analysts expect from CLX next quarter?
The consensus EPS estimate for The Clorox Company for the quarter ending Dec 31, 2026 is $0.98 from 15 analysts, with estimates from $0.87 to $1.05.
How often does CLX beat earnings estimates?
The Clorox Company beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +13.40%.
CLX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors